ログインVERI+CLUB へログインが必要です。
メールアドレス
パスワード

パスワードを忘れた方

STEMCELL Technologies STEMdiff STEMdiff Megakaryocyte Kit

  • 研究用
  • 新製品

STEMdiff™ Megakaryocyte Kit(ST-100-0900)は、ヒトの胚性幹(ES)細胞および人工多能性幹(iPS)細胞から、血小板放出能を有しCD41aおよびCD42bを発現する倍数体巨核球へと、無血清かつフィーダーフリーの条件下で分化させるため培地キットです。簡易な2次元培養による17日間の分化プロトコールを2段階で実施します。

第一段階(12日間)では、STEMdiff™ Hematopoietic Supplement A、次いでSupplement MK1を基礎培地に添加し、細胞を巨核球分化傾向をもつ造血前駆細胞へと誘導します。第一段階終了時に、培養上清から造血前駆細胞を容易に回収できます。第二段階ではこれをさらに5日間、Supplement MK2とStemSpan™ SFEM IIを用いて成熟巨核球へと分化させます。
分化プロトコール終了時(17日目)に細胞は通常405 ± 54倍(95% CI)まで増幅し、平均で71 ± 3.3%(95 CI)がCD41aおよびCD42bを共発現します。

STEMdiff™ Megakaryocyte Kitは、mTeSR™1(ST-85850)、mTeSR™ Plus(ST-100-0276)、またはTeSR™-AOF(ST-100-0401)で維持したヒトES/iPS細胞(hPSC)の分化に最適化されています。

2018/05/14 12:00の製品情報

VERI+NETのご注文はこちらから

本製品は研究目的にのみ使用し、人や動物の医療用・臨床診断用・食品用としては使用しないようにご注意ください。

製品の特長

STEMdiff™ Megakaryocyte Kitをもちいて、hPSCから血小板放出能を示す高倍数性の巨核球へと分化させることができます

  • 血清・フィーダー不使用のため、ばらつきを抑えられます
  • 複数のhPSC株にわたって巨核球を安定的に得られます
  • インプットするhPSCあたり高収量の巨核球を生成できます
  • 遺伝子編集や、大規模なフィーダーフリー培養に適しています

巨核球分化のプロトコール

100-0900-Fig1.jpg

Figure 1. Megakaryocyte Differentiation Protocol
The 17-day protocol includes two main stages: a 12-day stage to differentiate human embryonic stem (hES) or induced pluripotent stem (hiPS) cells into megakaryocyte-biased hematopoietic progenitor cells (HPCs), and a 5-day stage to further differentiate hES or hiPS cell-derived HPCs into mature megakaryocytes (MKs). On Day -1, hES or hiPS cells are plated as aggregates (100 - 200 μm diameter, ~100 cells per aggregate) at a density of 10 ‑ 20 aggregates/cm2 in mTeSR™1, mTeSR™ Plus, or TeSR™-AOF on Corning® Matrigel®-coated plates. After attaching overnight and confirming the number of adhered colonies is within 4 - 10 colonies/cm2, mesoderm induction is initiated by replacing TeSR™ medium with Medium A (STEMdiff™ Hematopoietic Basal Medium + STEMdiff™ Hematopoietic Supplement A). On Day 3, the medium is changed to Medium MK1 (STEMdiff™ Hematopoietic Basal Medium + STEMdiff™ Megakaryocyte Supplement MK1) for endothelial-to-hematopoietic transition (EHT) and hematopoietic specification. During this phase, hES or hiPS cell-derived HPCs emerge from an adherent layer of endothelial cells and are released into suspension. On Day 12, HPCs in suspension are harvested and replated in Medium MK2 (StemSpan™ SFEM II + STEMdiff™ Megakaryocyte Supplement MK2) at a density of 1 - 3.5 x 105 cells/mL and cultured for 5 days to generate mature MKs.

データ紹介

100-0900-Fig2.jpg

Figure 2. hPSCs Differentiate to Megakaryocyte-Erythroid Progenitors During 12 Days of Culture
hES and hiPS cells were induced to differentiate to megakaryocyte-erythroid biased HPCs following the protocol described in Figure 1. On Day 12, cells were harvested from the supernatant and analyzed for expression of CD41a, CD42b, CD34, and GlyA by flow cytometry. Dead cells were excluded by light scatter profile and propidium iodide (PI) staining. (A) Representative flow cytometry plots for hES-derived (H9) cells on Day 12. The cells show high levels of CD41a and CD42b as well as of CD34 and GlyA expression, indicating that the protocol supports differentiation of hPSCs to megakaryocyte-erythroid progenitors by Day 12. (B) Frequencies and numbers of CD41a+CD42b+ cells per input cell for two hES cell lines (H1 and H9) and two hiPS cell lines (WLS-1C and STiPS-R038). The average frequency of viable CD41a+CD42b+ cells on Day 12 ranged between 33% and 62%. The average yield of CD41a+CD42b+ cells generated per input cell ranged between 72 and 174. Data are shown as mean ± SEM (n = 7 for H1, n = 20 for H9, n = 19 for WLS-1C, n = 7 for STiPS-R038).

100-0900-Fig3.jpg

Figure 3. hPSC-Derived HPCs Efficiently Expand and Differentiate to CD41a+CD42b+ Megakaryocytes During an Additional 5 Days of Culture
hPSC-derived HPCs on Day 12 were cultured for 5 additional days in Medium MK2 to promote differentiation into mature MKs following the protocol described in Figure 1. Cells were harvested and analyzed for expression of CD41a, CD42b, CD34, and GlyA by flow cytometry. Dead cells were excluded by light scatter profile and PI staining. (A) Representative flow cytometry plots for hES-derived (H9) cells on Day 17. The cells showed high levels of CD41a and CD42b and low levels of GlyA and CD34 markers, indicating differentiation to megakaryocytes. (B) Frequencies and numbers of CD41a+CD42b+ MKs per input cell for two hES cell lines (H1 and H9) and two hiPS cell lines (WLS-1C and STiPS-R038). The average frequency of viable CD41a+CD42b+ cells on day 17 ranged between 56% and 77%. The average yield of CD41a+CD42b+ MKs generated per input cell ranged between 223 and 425. Data are shown as mean ± SEM (n = 12 for H1, n = 29 for H9, n = 27 for WLS-1C, n = 12 for STiPS-R038).

100-0900-Fig4.jpg

Figure 4. hPSC-Derived Megakaryocytes Generated Using STEMdiff™ Megakaryocyte Kit Are Polyploid
hPSC-derived MKs obtained using STEMdiff™ Megakaryocyte Kit display mature and adult-like features: cellular enlargement and polyploidization. (A) A representative bright-field image taken on Day 17 showing large MKs derived from H1 cells (10X magnification). (B) Representative immunofluorescence images taken on Day 17 showing that CD41a+ MKs derived from H1 and WLS-1C cells are polyploid (20X and 63X magnification, respectively). The cells were formaldehyde-fixed and stained with a fluorescein-conjugated antibody against surface marker CD41a (green), and DAPI (blue). (C) A representative cytospin of MKs derived from H9 cells on Day 17 showing high ploidy (40X magnification, May-Grunwald Giemsa stain). (D) Representative flow cytometry histogram and scatter plot showing the DNA ploidy profile of ethanol-fixed MKs derived from H9 cells on Day 17. The DNA content was determined by the quantity of PI staining, with different peaks on the histogram representing 2N, 4N, and 8N+ cells. Ploidy analysis was done on gated CD41a+ cells. (E) Ploidy distribution of MKs generated from two hES cell lines (H1 and H9) and two hiPS cell lines (WLS-1C and STiPS-R038). The average ploidy distributions of CD41a+ cells on Day 17 were 66%, 24.5%, and 9.5% for 2N, 4N, and 8N+, respectively. Data are shown as mean ± SEM (n = 6 for H1, n = 28 for H9, n = 19 for WLS-1C, n = 10 for STiPS-R038).

100-0900-Fig5.jpg

Figure 5. hPSC-Derived Megakaryocytes Generated Using STEMdiff™ Megakaryocyte Kit Yield Platelet-Like Particles
hPSC-derived MKs obtained using STEMdiff™ Megakaryocyte Kit are capable of proplatelet formation to yield functional platelet-like particles (PLPs). (A) A representative bright-field image taken on Day 17 showing MKs derived from H1 cells formed proplatelets, (long cytoplasmic protrusions,10X magnification). (B) Representative flow cytometry forward/side scatter profile of MKs and PLPs and histogram of PLPs derived from H9 cells on Day 17. The PLP gate is based on control platelets (PLTs) prepared from fresh blood. Cells were also stained with antibodies against CD41a, CD45, and GlyA for PLP characterization and enumeration. PLPs showed a high level of CD41a expression (and no CD45 and GlyA expression, data not shown) as in control PLTs. Grey filled histogram represents CD41a Fluorescence Minus One (FMO) control. (C) Numbers of PLPs generated per MK on Day 17 for two hES cell lines (H1 and H9) and two hiPS cell lines (WLS-1C and STiPS-R038). PLPs and MKs were enumerated based on the number of CD41a+CD45-GlyA- cells in the PLP gate and viable CD41a+ cells in the MK gate, respectively. The average yield of PLPs generated per MK ranged between 3.2 and 5.1. Data are shown as mean ± SEM (n = 12 for H1, n = 28 for H9, n = 27 for WLS-1C, n = 12 for STiPS-R038).

100-0900-Fig06.jpg

Figure 6. STEMdiff™ Megakaryocyte Kit Produces More Megakaryocytes and Platelet-Like Particles than Other Published Protocols
hES and hiPS cells were differentiated into MKs using STEMdiff™ Megakaryocyte Kit and using four different published protocols from the literature with modifications. (A) Frequencies and numbers of CD41a+CD42b+ MKs per input cell for two hES cell lines (H1 and H9) and two hiPS cell lines (WLS-1C and STiPS-R038) were analyzed by flow cytometry as shown in Figure 2. (B) Numbers of PLPs generated per input cell were enumerated as described in Figure 5. Compared to the published protocols, STEMdiff™ Megakaryocyte Kit produced 10- to 40-fold more CD41a+CD42b+ MKs and 6- to 23-fold more PLPs per input cell. P values were calculated using a one-way ANOVA followed by Dunnett’s post hoc test (*p < 0.05, **p < 0.01). Data are shown as mean ± SEM (n = 7 - 8).

関連製品

この製品を見ている人は、
この製品情報も見ています。

製品についてのお問い合わせ

掲載製品の技術情報、在庫や価格など、各窓口にお気軽にご相談ください。

法規制アイコン
毒 毒物及び劇物取締法の「毒物」(法第2条別表第1)を含む製品です。
劇 毒物及び劇物取締法の「劇物」(法第2条別表第2)を含む製品です。
カ 「遺伝子組換え生物等の使用等の規制による生物の多様性の確保に関する法律」(通称カルタヘナ法)の使用規制対象となる製品です。 ご使用に際しては規制に即し適切にお取り扱いください。
労 労働安全衛生法の「名称等を表示すべき危険物及び有害物」(法第57条)、あるいは「名称等を通知すべき危険物及び有害物」(法第57条第2項)を含む製品です。
向 麻薬及び向精神薬取締法の「麻薬向精神薬原料」(法第2条の7、別表第4)を含む製品です。